2026 ACC/AHA Guidelines on Cholesterol Management: Key Changes and Implications
Earlier this year, the American College of Cardiology (ACC) and the American Heart Association (AHA) released their updated 2026 Guideline on the Management of Dyslipidemia, which replaces the previous 2018 guideline on blood cholesterol management. This new guideline reflects a shift in the approach to cholesterol and heart disease, emphasizing personalized treatment strategies and specific LDL cholesterol targets.
Research from Mass General Brigham indicates that nearly one in three adults in the United States without a history of heart disease have LDL, or “bad,” cholesterol levels that exceed the goals set by the 2026 guideline. For individuals who have experienced a heart attack, stroke, or other cardiovascular events, this figure rises dramatically to nearly four out of five.
The 2026 guideline sets forth specific LDL cholesterol targets, recommending that very high-risk individuals maintain levels below 55 milligrams per deciliter (mg/dL), while those at lower risk should aim for levels below 70 mg/dL or 100 mg/dL, depending on their baseline risk. Importantly, the guidelines stress the need for personalized targets tailored to individual patient profiles.
Experts consulted by Medical News Today highlighted several key takeaways from the updated guidelines. Notably, the introduction of specific LDL cholesterol targets, universal screening for lipoprotein(a) (Lp(a)), and recommendations for cholesterol screening starting in childhood at ages 9-11, with follow-ups at ages 19-21 and every five years thereafter for adults. This approach aims to identify and address lifelong cardiovascular risk early.
A new risk calculator named PREVENT has also been introduced, expanding the age range for screening from 30-79 years, up from the previous 40-75 years. This tool provides estimates of heart disease risk over 10 and 30 years and incorporates kidney function as a risk factor.
The guideline advises that every adult should undergo testing for Lp(a) at least once, with recommendations for testing first-degree relatives if Lp(a) levels are elevated. Additionally, it suggests that calcium score testing be performed for men aged 40 and older and women aged 45 and older when assessing lipid-lowering therapy for those at intermediate risk.
Experts emphasize that treatment decisions should not be based solely on LDL cholesterol levels but rather on a comprehensive assessment of total cardiovascular risk, including family history and other health conditions. This nuanced approach recognizes that two individuals with identical LDL levels may have vastly different risks for heart attack or stroke based on their overall health profile.
Patients, especially those at higher risk, are encouraged to discuss their LDL targets with their healthcare providers. The guidelines note that many Americans remain undertreated for high cholesterol, often due to a lack of awareness or symptoms until significant damage has occurred.
Challenges such as limited access to primary care and concerns about medication side effects contribute to this under-treatment. The guidelines also address disparities in statin use among different racial and ethnic groups, highlighting that women and individuals from minority backgrounds are less likely to be offered statin therapy.
The guideline supports measuring Lp(a) levels, as elevated Lp(a) is a hereditary risk factor for cardiovascular disease. It is recommended that individuals with high Lp(a) levels receive more aggressive management of modifiable risk factors.
While statins remain a primary treatment option, alternatives such as ezetimibe, bempedoic acid, and PCSK9 inhibitors are also discussed for patients who may experience side effects from statins. The guideline emphasizes that dietary supplements, including fish oil, have not demonstrated significant LDL-lowering effects and should not be relied upon as substitutes for proven therapies.
Overall, the 2026 ACC/AHA guidelines represent a significant evolution in cholesterol management, focusing on personalized care and comprehensive risk assessment to improve cardiovascular health outcomes.




